BCL2 and hepatocellular carcinoma: Combining the treatment using 52 with sorafenib resulted in the induction of apoptosis in HepG2-SR (sorafenib-resistant hepatoma cells) and Huh7-SR (sorafenib-resistant Huh-7 cells) via the overexpression of Bax and downregulation of Bcl-2 expression, as well as an increase in cleaved caspase-3 and poly (ADP—ribose) polymerase.